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Abstract
Serum bilirubin levels have been associated with polymorphisms in the UGT1A1 promoter in normal populations and in
patients with hemolytic anemias, including sickle cell anemia. When hemolysis occurs circulating heme increases, leading to
elevated bilirubin levels and an increased incidence of cholelithiasis. We performed the first genome-wide association study
(GWAS) of bilirubin levels and cholelithiasis risk in a discovery cohort of 1,117 sickle cell anemia patients. We found 15 single
nucleotide polymorphisms (SNPs) associated with total bilirubin levels at the genome-wide significance level (p value
,561028). SNPs in UGT1A1, UGT1A3, UGT1A6, UGT1A8 and UGT1A10, different isoforms within the UGT1A locus, were
identified (most significant rs887829, p = 9.08610225). All of these associations were validated in 4 independent sets of
sickle cell anemia patients. We tested the association of the 15 SNPs with cholelithiasis in the discovery cohort and found a
significant association (most significant p value 1.1561024). These results confirm that the UGT1A region is the major
regulator of bilirubin metabolism in African Americans with sickle cell anemia, similar to what is observed in other
ethnicities.
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Introduction
Cholelithiasis is the most common gastrointestinal disease to
require hospitalization worldwide [1]. Most gallstones are
primarily comprised of cholesterol; however, in certain patient
risk groups, bile pigment stones are extremely common and
represent a significant cause of morbidity. These stones are
associated with increased serum unconjugated bilirubin levels,
which occur in a number of conditions including hemolytic
anemia. In other patient groups, ineffective erythropoiesis, ileal
diseases, or gastrointestinal resections producing increased colonic
spillage of bile salts, predispose to bile pigment stones [2].
Patients with sickle cell disease (SCD), particularly those with
sickle cell anemia (homozygosity for HBB glu6val), are at risk for
bile pigment cholelithiasis due to the association of this disease
with hemolysis which produces an unconjugated hyperbilirubin-
emia [3]. Cholelithiasis occurs in up to 70% of these patients,
resulting from the precipitation of polymerized calcium bilirubi-
nate within the gallbladder lumen when the ion product of calcium
and unconjugated bilirubin exceeds its solubility. Up to 50% of
these patients undergo cholecystectomy at some point during their
lifetimes, suggesting increased associated morbidity, creating a
need for hospitalization, and potential mortality from infectious or
other complications related to this process(1).
Cholelithiasis risk, for both cholesterol and bile pigment stones,
is thought to be partially mediated by genes impacting bilirubin
metabolism [4,5,6]. Genome-wide association studies (GWAS) of
three large Caucasian cohorts have identified single nucleotide
polymorphisms (SNPs) in UGT1A1 that are responsible for 18% of
clinical variability of serum bilirubin [7]. Sequencing of the
UGT1A1 gene in patients with Gilbert’s syndrome, associated with
unconjugated hyperbilirubinemia, revealed that an important
modulator of enzyme activity is the length of TA repeats in the
promoter region; the greater the number of repeats being
associated with the highest serum bilirubin levels and cholelithiasis
risk [8,9].
Genome-wide studies examining hyperbilirubinemia and cho-
lelithiasis risk have not been performed in persons of African
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descent with sickle cell anemia. However, sequencing of UGT1A1
has been undertaken in SCD cohorts in Guadeloupe, Portugal,
Jamaica, India and the United States; genotyping of 324 SCD
children from the Cooperative Study of Sickle Cell Disease
(CSSCD) revealed that the common (TA)6 and (TA)7 alleles were
present in 75% [10–15]. The (TA)7/(TA)7 genotype was
associated with increased serum bilirubin levels and cholelithiasis
risk compared with the (TA)6/(TA)7 and (TA)6/(TA)6 genotypes
across cohorts with suggestions that those with a (TA)8 allele are at
highest risk, suggesting a similar pattern of inheritance as observed
in Caucasians [10–15]. Treatment with hydroxyurea, known to
decrease the hemolytic rate in sickle cell anemia patients, was
unable to decrease bilirubin levels to normal levels in those with
the (TA)7/(TA)7 genotype suggesting that this genetic defect may
represent a new pharmacologic target for these patients [14].
One of the reasons for the focus on UGT1A1 in genetic studies
relates to its known importance in bilirubin metabolism [8,9].
Upon release into the plasma, heme is metabolized to bilirubin via
the actions of heme oxygenase-1. Bilirubin is poorly water soluble
and in order for excretion to occur, disruption of its hydrogen
bonds via a process termed glucuronidation, or conjugation, is
essential. Glucuronidation of bilirubin is mediated by a family of
enzymes termed the uridine-diphosphoglucuronate glucuronosyl-
transferases (UGT). Of these, UGT1A1 is the most important
regulator of this process clinically and is one of the isoforms of the
UGT1A gene complex comprised of 9 transcriptional units.
Unconjugated or indirect bilirubin is responsible for all of the
toxic effects of hyperbilirubinemia, supporting the clinical
importance of this class of enzymes. Additionally, as alluded to
previously, genetic studies of other patient populations character-
ized by hyperbilirubinemia, Gilbert’s syndrome and cystic fibrosis,
have demonstrated an association between genetic variants within
dinucleotide repeats in the promoter of UGT1A1 and bile pigment
stone formation [7].
We conducted a GWAS of serum total bilirubin in the largest
number of African American sickle cell anemia patients studied to
date to determine if genetic variants played a role in the increased
risk of cholelithiasis observed in this population. Our analysis
shows that UGT1A1 is the major regulator of bilirubin levels in
African Americans with sickle cell anemia, and that genetically
mediated differences in bilirubin conjugation play an important
role in cholelithiasis risk in these patients.
Materials and Methods
Ethics Statement
All studies were approved by the Institutional Review Board of
Boston Medical Center, Duke University, University of Pittsburgh,
Johns Hopkins University, Washington University and the
University of North Carolina at Chapel Hill. Additionally, IRB
approval was acquired from all of the sites participating in the
Walk-PHaSST, Multicenter Study of Hydroxyurea Use and SITT
trials for subject enrollment. All patients signed informed written
consent for participation in these studies.
Study Subjects
The discovery set consisted of 1,117 African American subjects
from the CSSCD [16,17]. The replication cohorts were comprised
of 195 subjects from the Multicenter Study of Hydroxyurea
(MSH), 522 subjects from the Pulmonary Hypertension and Sickle
Cell Disease with Sildenafil Therapy (Walk-PHaSST) study
(NCT00492531) [18], 530 subjects from the Outcome Modifying
Genes study (referred to subsequently as ‘‘Duke’’) that enrolled
patients from Duke University Medical Center, the University of
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North Carolina Chapel Hill, Emory University, East Carolina
University Comprehensive Sickle Cell Centers, and the Carolinas
Health Center, and 905 samples from the SITT silent cerebral
infarct trial (NCT00072761). The timing of each of these studies
impacted hydroxyurea use. None of the patients from the CSSCD
discovery set were treated with hydroxyurea as recruitment for this
study concluded in 1998. To eliminate potential confounding
effects of hydroxyurea, in the MSH, pre-hydroxyurea levels of
total bilirubin were utilized [19].
Genotyping
The DNA from the CSSCD, MSH, and Walk-PHaSST samples
were genotyped at Boston University using the Illumina
Human610-Quad SNP array, with approximately 600,000 SNPs
and the Illumina HumanCNV370-duo bead chip (MSH). The
Duke samples were also genotyped using the Human610-Quad
SNP array, whereas the SITT cohort was genotyped in two stages.
In stage 1, a subset of 573 recruited samples was genotyped at the
Center for Inherited Disease Research (CIDR) using IIIumina
HumanHap650Y array. The genotype data for the remaining 509
samples were generated at the Center for Disease Control (CDC)
in collaboration with Washington University using Illumina
Infinium HumanOmni1-Quad array. To infer un-typed SNPs
and fill-in missing data across Omni1M and HumanHap650Y
platforms, imputation was performed by using Hidden Markov
model implemented in MaCH software [20]. All samples
genotyped at Boston University were processed according the
manufacturer’s protocol and BeadStudio Software was used to
make genotype calls utilizing the Illumina pre-defined clusters.
Samples with less than a 95% call rate were removed and SNPs
with a call rate ,97.5% were re-clustered. After re-clustering,
SNPs with call rates.97.5%, cluster separation score..25, excess
heterozygosity between 2.10 and .10, and minor allele frequency
.5% were retained in the analysis. We used the genome-wide
identity by descent analysis in PLINK to discover unknown
relatedness. Pairs with identity by descent measurements greater
Table 2. Patient Characteristics of the Duke and SITT cohorts.
Clinical Variable Duke SITT
Overall (N=530) Men (N=242) Women (N=288) Overall (N=905) Men (N=480) Women (N=425)
Log Total Bilirubin (mg/dL)* 0.83 (0.7) 0.89 (0.8) 0.78 (0.7) 1.12(0.6) 1.16(0.6) 1.08(0.6)
Reticulocyte (%) 10.35 (6.0) 10.22 (6.0) 10.45 (6.1) 11.89(5.5) 12.01(5.6) 11.75(5.4)
AST (units/dL) 46.56 (34.6) 47.69 (29.2) 45.61 (38.5) NA NA NA
ALT (units/dL) 30.93 (28.2) 32.41 (28.7) 29.69 (27.8) NA NA NA
Hemoglobin (g/dL) 8.75 (1.8) 9.20 (2.1) 8.40 (1.6) 8.12(1.1) 8.01(1.1) 8.26(1.1)
LDH (mg/dL) NA NA NA NA NA NA
Age (years) 33.67 (11.9) 32.34 (11.0) 34.79 (12.6) 8.96(2.4) 9.07(2.5) 8.84(2.4)
Summary statistics of patient characteristics in the DUKE and SITT studies. For each study, the first column reports statistics (mean and standard deviation) for all
patients included in the analysis and the second and third columns report statistics stratified by gender.
doi:10.1371/journal.pone.0034741.t002
Figure 1. Plot of serum bilirubin among 90 sibling pairs in the CSSCD (A) and 200 pairs of unrelated individuals randomly selected
from the CSSCD (B). In each scatter plot, the x- and y-axes show levels of total bilirubin. The correlation coefficient in the 90 sibling pairs was 0.27,
while the average correlation coefficient of bilirubin levels in the pairs of unrelated individuals was 20.002.
doi:10.1371/journal.pone.0034741.g001
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than .2 were deemed to be related subjects. Related subjects within
individual or different studies were removed. We also removed
samples with inconsistent gender findings defined by heterozygos-
ity of the X chromosome and gender recorded in the database.
Quality control parameters for the DUKE and SITT samples
were comparable. In SITT, a 98% cutoff was used for both the
sample and SNP call rates in the combined dataset (n = 1082), and
resulted the exclusion of 6 individuals and 1,260 SNPs from the
study. Seventy seven samples were identified as first-degree
relatives (pairs with identity by descent measurements . 0.4),
and 1 individual from each pair was removed. Twenty six
individuals were identified as genetic outliers using EIGEN-
STRAT (.6 standard deviations on any of the top ten principal
components) and removed. Additionally, 68 samples were also
dropped from the study, due to missing phenotype data, leaving
905 samples for subsequent analysis.
Phenotype
Serum total and direct bilirubin, lactate dehydrogenase (LDH),
hemoglobin concentrations, and reticulocyte counts were mea-
sured using automated chemical and hematologic analyzers at the
individual medical centers participating in these studies.
For the CSSCD patients, longitudinal bilirubin measurements
were collected from phases 1, 2, and 3 of the study [16]. Only
steady state measurements were used (4 months removed from
blood transfusion). The longitudinal measurements of 3,250 study
patients were analyzed using a Bayesian hierarchical mixed model
that included a random effect per patient to account for the
repeated measurements, as well as random intercept and age
effects that were allowed to vary with the clinics. The random
intercept and age effects were used to remove the between-site
systematic differences. Markov Chain Monte Carlo method in
Openbugs was used to estimate the predicted total bilirubin values,
and log-transformed median predicted values were used as the
phenotype for the GWAS. The details of the analysis are available
as (Information S1). For MSH, Duke, Walk-PHaSST and SITT
patients, the log transformed baseline total bilirubin was used.
CSSCD subjects were assessed for gallstones by cholecystogram,
plain film report, and abdominal ultrasound. A combination of
questionnaires and medical records were utilized to determine a
history of cholelithiasis or cholecystectomy. The cholelithiasis
phenotype was dichotomized into: a) those who had gallstones (or
history of), a history of cholecystectomy, a nonfunctional
gallbladder; or b) none of these conditions. Of the 1,062 CSSCD
patients with gallstone information, 348 had gallstones, or a
nonfunctional gallbladder, cholecystectomy or a history of one of
these events.
Heritability of Total Bilirubin
To further examine heritability of serum bilirubin in the
CSSCD population, we examined the correlation of serum
bilirubin in 90 sibling pairs. As a comparison, we randomly
selected serum bilirubin values for 200 unrelated pairs 1,000 times
to get an average of the estimated correlation among unrelated
individuals.
Description of GWAS and Secondary Genetic Association
Analyses
The association between total bilirubin levels and each SNP that
passed quality control was tested using multiple linear regression,
adjusting for age and gender using the additive and genotypic
model in PLINK software. Age and gender were both included as
covariates, as both were found to have a significant association
with total bilirubin levels (p,0.0001 for both covariates). The
minor allele was the coded allele in the additive model. To control
for population stratification, a separate GWAS was performed on
the discovery set adjusting for age, gender and the top ten
principal components calculated using EIGENSOFT [21].
Haploview was employed to generate LD heatmaps using
genotype data from the CSSCD. The SNPs that reached genome-
Figure 2. Summary of the GWAS data from the CSSCD Cohort. The Manhattan plot (A) displays the –log10(p value) of the associations tested
in the CSSCD cohort using the additive model. Color bands represent chromosomes, and SNPs are ordered by their physical position within each
chromosome. The large spike in chromosome 2 corresponds to the UGT1A1, UGT1A3, UGT1A8 and UGT1A10 regions. The QQ-plot (B) displays the
observed (y-axis) versus expected (x-axis) –log10 (p-value). From the QQ plot, there is minimal to no inflation in the test statistic.
doi:10.1371/journal.pone.0034741.g002
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Figure 3. LD Structure in the CSSCD Cohort. LD plots for regions in genes UGT1A1, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8,
UGT1A9 and UGT1A10 on chromosome 2 in the CSSCD subjects. The LD plot was generated using Haploview 4.2. Each diamond represents the D’
value between two SNPs. The LD color scheme is: white D’,1 and LOD,2, blue D’ = 1 and LOD,2; shades of pinkish-red D’,1 and LOD$2 and
bright red D’ = 1 and LOD$2.
doi:10.1371/journal.pone.0034741.g003
Table 4. Single Nucleotide Polymorphisms Associated with Cholelithiasis.
SNP Chr BP Coded Allele Non-Coded Allele MAF OR P value
rs7586110 2 234255266 C A 0.2632 1.366 0.05779
rs10168155 2 234261575 A G 0.373 1.393 0.02858
rs10168416 2 234261826 G C 0.2402 1.417 0.03765
rs6759892 2 234266408 C A 0.3763 1.415 0.02134
rs1105880 2 234266704 G A 0.3628 1.408 0.02277
rs2070959 2 234266930 G A 0.2468 1.4 0.04248
rs1105879 2 234266941 C A 0.303 1.356 0.05056
rs17863787 2 234275833 C A 0.2498 1.324 0.09915
rs3755319 2 234332321 A C 0.2913 0.561 0.001284
rs887829 2 234333309 A G 0.4532 1.715 0.00032
rs6742078 2 234337378 A C 0.433 1.635 0.001044
rs4148324 2 234337461 C A 0.4459 1.654 0.000878
rs3771341 2 234337978 A G 0.3998 1.661 0.00087
rs4148325 2 234338048 A G 0.4525 1.757 0.000175
rs4148326 2 234338201 A G 0.3874 0.524 0.000115
Results of SNP association analysis with cholelithiasis in the CSSCD study using the additive model. The minor allele is the coded allele, and the OR is the odds for
cholelithiasis in carriers of one extra copy of the coded allele.
doi:10.1371/journal.pone.0034741.t004
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wide significance in the CSSCD sample were analyzed for
association in the other cohorts. In SITT, the genetic associations
were performed after adjustments for the same covariates (age,
gender and top ten principal components). To account for the
uncertainty of imputed data, the estimated allele dosage was
analyzed using ProABEL under a linear regression framework [22].
Duke only controlled for age and gender, because previous analyses
had indicated there was not appreciable population stratification in
that data set. In a secondary analysis, SNPs that achieved genome-
wide significance from the additive model were tested for association
with the cholelithiasis in the CSSCD cohort. This association was
tested using an additive multiple logistic regression model, adjusting
for age. The same SNPs were also tested for association with LDH,
reticulocyte counts and hemoglobin concentration, using the same
Bayesian hierarchical model.
Results
Patient Characteristics and Heritability of Total Bilirubin
Levels
Patient characteristics for each cohort are shown in Tables 1
and 2. The CSSCD cohort was younger than the MSH, Duke,
and Walk-PHaSST cohorts. Each of the cohorts were equally
divided between males and females. Examination of the serum
bilirubin levels amongst 90 sibling pairs revealed a positive
correlation (r = 0.270, p = 0.009), consistent with heritability of
bilirubin levels (Figure 1A). In contrast, there was no correlation
amongst 1,000 randomly selected pairs (r =2.002 average p
value = 0.502, Figure 1B).
Association Between UGT SNPs and Serum Bilirubin
Levels
After our quality control procedures, 569,615 SNPs were
analyzed in the GWAS of serum bilirubin in the CSSCD.
Figure 2A shows the Manhattan plot, with the results of the
GWAS for the additive model and the large spike of significant
associations in chromosome 2. The QQ plot (Figure 2B) shows no
inflation (lambda factor, l=1.01) suggesting that there is no
confounding by population stratification. To confirm this, we
repeated the analysis after adjustment for the top ten principal
components and the magnitude and significance of the top SNPs
did not change. Fifteen SNPs reached genome-wide significance
for both the genotypic and additive models and we report only the
results from the additive model (Table 3). These genes are located
on a contiguous part of chromosome 2 of the UGT1 region. The
linkage disequilibrium (LD) structure of these SNPs in Figure 3
shows two blocks in LD, although all 15 SNPs are in very strong
LD (D’.0.53) (the LD structure of these SNPs can be show in
terms of r2 in Information S1). To determine if these 15 SNPs
were part of one or multiple independent signals, another GWAS
was performed adjusting for age, sex and our top SNP, rs887829.
None of the fourteen SNPs showed a significant association with
serum bilirubin after this adjusted analysis (complete results can be
seen in Information S1), thus suggesting that these 15 SNPs are a
part of the same signal. A complete list of the SNPs with a p value
less than 5610205 consistent with genome-wide significance can
be found in Information S1. An increase in the number of minor
alleles in all SNPs except rs4148326 and rs3755319 was associated
with an increase in log total bilirubin (effect sizes ranging from
0.108 to 0.1838), so that the less common alleles are the risk alleles;
however, the other two SNPs showed effect estimates in the
opposite direction (effect sizes ranging from 2.13 to 2.14), so that
the minor alleles are associated with lower levels of serum
bilirubin. Only four of the SNPs that reached genome-wide
significance in the CSSCD population were available for
genotyping on the 370K array used for the MSH samples, while
all of them were genotyped in the Duke, Walk-PHaSST and SITT
cohorts. All of the SNPs were significantly associated with bilirubin
levels and had a regression coefficient in the same direction in both
the discovery and replication sets (Table 3).
SNPs Associated with Bilirubin Levels are also Associated
with Cholelithiasis
Table 4 shows the association between the 15 genome-wide
significant SNPs and the odds for cholelithiasis. Twelve of the
15 SNPs were significantly associated with cholelithiasis (p ,.05)
and all of them had associated odds ratios for cholelithiasis in a
direction consistent with that observed in the analysis of total
bilirubin: An increase in the number of risk alleles for all SNPs
except rs4148326 and rs3755319 was associated with an increased
odds for cholelithiasis (odds ratios ranging from 1.324 to 1.757).
The other two SNPs showed effect estimates in the opposite
direction (odds ratios of .524 and .561). We also tested whether
these 15 SNPs were significantly associated with LDH levels,
hemoglobin concentration and reticulocyte count to see if there
was an association with markers of hemolysis. None of the SNPs
showed an association with LDH, hemoglobin concentration or
reticulocyte count (Table 5).
Discussion
Intravascular hemolysis in sickle cell anemia patients produces
increased circulating heme levels and has been associated with
clinical complications including cholestatic jaundice and choleli-
thiasis [10,23–25,26–28] Unconjugated hyperbilirubinemia is a
risk factor for the development of bile pigment stones in sickle cell
disease and other hemolytic anemias [12,29–41]. Typically,
bilirubin is formed from metabolism of heme, which is derived
Table 5. Association Analysis with LDH, Reticulocyte Counts
and Hemoglobin Concentration.
SNP LDH Reticulocytes Hemoglobin
b pval b pval b pval
rs7586110 20.01206 0.235 0.01255 0.4964 0.02221 0.6891
rs10168155 20.00587 0.5304 20.0032 0.8501 0.04552 0.3687
rs10168416 20.0042 0.6886 0.01099 0.563 0.02353 0.6808
rs6759892 20.00604 0.5171 0.001128 0.9466 0.04249 0.4034
rs1105880 0.000316 0.9729 7.16E205 0.9966 0.04007 0.4277
rs2070959 20.00319 0.7579 0.01636 0.3834 0.003175 0.9552
rs1105879 20.00135 0.8891 0.02488 0.1554 0.0182 0.7298
rs17863787 0.00116 0.9146 0.006013 0.7586 0.004455 0.9399
rs3755319 20.00043 0.9653 0.006524 0.7188 0.01732 0.7509
rs887829 20.00528 0.558 20.01726 0.2922 0.06559 0.1825
rs6742078 20.00786 0.3855 20.01868 0.2558 0.05936 0.2303
rs4148324 20.00463 0.6104 20.02468 0.1339 0.06086 0.2193
rs3771341 20.00911 0.3252 20.01876 0.2654 0.07966 0.1158
rs4148325 20.00799 0.3732 20.02165 0.1877 0.06967 0.1576
rs4148326 0.003204 0.7309 0.01245 0.462 0.02886 0.5721
Results of SNP association analysis with other hemolytic phenotypes including
hemoglobin, LDH and reticulocyte count in the CSSCD Study.
doi:10.1371/journal.pone.0034741.t005
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principally from erythrocytic hemoglobin. Heme is oxidatively
metabolized by heme oxygenase-1 into biliverdin, which is
subsequently reduced enzymatically by biliverdin reductase to
bilirubin. Upon formation, bilirubin is water insoluble, due to the
presence of internal hydrogen bonding that creates a contorted
molecule structure, inhibiting solubility. This form of bilirubin,
termed unconjugated or indirect bilirubin, is responsible for all of
the toxic effects of bilirubin observed clinically. To permit
excretion, bilirubin complexes with albumin and is transported
via the bloodstream to the liver, where it undergoes glucuronida-
tion by the UGT family of enzymes; UGT1A1 is the only one with
clinical relevance in humans [42]. UGT1A is a gene complex
composed of 9 transcriptional units encoding an isoform of the
UGT gene [30,31]. The most common genetic cause of impaired
bilirubin glucuronidation occurs in Gilbert’s syndrome, which
follows an autosomal recessive inheritance pattern and most
commonly affects Caucasians of European descent [43,44].
Clinically, these patients have a mild indirect hyperbilirubinemia,
which worsens during periods of stress or febrile illnesses [45].
Genetic studies of these patients have identified a dinucleotide
repeat polymorphism (TA)5–8 in the TATA box of the UGT1A1
gene promoter that is associated with reduced UGT expression and
produces hyperbilirubinemia [30–31,37,46–47]. This polymor-
phism has also been observed in small cohorts of sickle cell anemia
patients suggesting a common pathogenic link between ethnically
divergent etiologies of indirect hyperbilirubinemia [5,10–15,33].
In the current study, genome-wide genetic screening of a large
cohort of sickle cell anemia patients not only confirmed these
findings but also supported their biological relevance.
In addition to defects in bilirubin metabolism, genetic
alterations in the glucuronidation pathway have been linked to
abnormalities in the hepatic metabolism of certain medications,
pre-disposition to cardiovascular disease and certain types of
malignancy suggesting a clinical level of importance beyond
cholelithiasis [35,42,48–53]. How this relates to the pathogenesis
of sickle cell anemia is not entirely clear clinically, but may be
worthy of future study.
In genetic studies of primarily Caucasian cohorts, cholelithiasis
and serum bilirubin levels are heritable traits. Family-based studies
show that the UGT locus accounted for a significant proportion of
the variation observed in both of these variables [18,54–56]. Our
study is the first to use GWAS to examine an African American
population with sickle cell anemia, a condition where hemolysis
predisposes patients to hyperbilirubinemia, to determine the
heritability of serum bilirubin levels. Fifteen SNPs in UGT1A1,
UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8 and
UGT1A9 reached genome-wide significance for association with
total bilirubin levels in the CSSCD cohort; 13 of these were also
associated with the presence or history of cholelithiasis. These
findings were confirmed in 4 other cohorts totaling 3,269 patients,
unusual for a rare disease such as sickle cell anemia, and
representing a greater number of patients than all of the previous
studies of this population combined.
SNPs we identified in the current study have been linked to
hyperbilirubinemia in other populations. SNP rs887829, the most
significant SNP associated with bilirubin levels identified in the
CSSCD, Duke and Walk-PHaSST cohorts, was previously
observed in associated with total bilirubin levels in a GWAS of
4,300 Sardinians [57]. This study also reported a significant
association with bilirubin and the SLCO1B3 locus; however, we
were unable to replicate these results in our study due to
unavailability or low MAF of the markers in our array. In a study
performed by Cheng et al. examining genetic variants associated
with serum bilirubin in 619 healthy African Americans revealed
that the top SNP was rs887829 (p = 1.77610222) [58]. This
suggests that this variant is not unique to African Americans with
sickle cell disease. It has been theorized that this SNP may confer
protection against malaria which may explain its penetrance
amongst African populations. SNP rs887829 is located in the
promoter region of UGT1A1, 221 bp upstream from the (TA)n
repeat sequence. Horsfall et al. found a strong association was
found between rs887829 and the (TA)7 and (TA)8 repeat sequence
suggesting that this may be a marker for the (TA)7/(TA)7 or 8
genotypes [34]. This proximity to the promoter element and
strong level of association suggest that rs887829 is a marker for the
(TA)n repeats and that additional sequencing of this gene would be
redundant [58]. SNP rs6742078, identified in the current study,
was associated with total bilirubin in a meta-analysis previously
performed by Johnson et al., including the Framingham Heart
Study, Rotterdam Study and Age, Gene, Environment and
Susceptibility-Reykjavik study cohorts [33]. In addition, SNPs
rs3755319, rs7586110, and rs6759892 were also found to be
significantly associated with total bilirubin in a cohort of 4,300
Sardinians [57]. SNP rs887829 was found to be associated with
cholelithiasis in a study published by Buch et al., in which a cohort
of 2,606 German cholelithiasis patients was compared with 1,121
South American controls (OR=1.73, p value .003) [11].
There was no association between LDH, hemoglobin concen-
tration or reticulocyte count, markers of hemolysis, and the SNPs
identified in the present study. A potential explanation for this is
the weak association between bilirubin levels and hemolytic rate.
While the "gold standard" for hemolysis is the red cell lifespan, this
is rarely performed and surrogate blood biomarkers such as
reticulocyte count, LDH, bilirubin and haptoglobin levels are used
clinically to estimate the degree of hemolysis. None of these
measures are specific for hemolysis. An elevated serum bilirubin
level in sickle cell anemia reflects multiple pathophysiologic
processes that include liver disease in addition to hemolysis and
therefore may lack the phenotypic specificity required for genetic
association studies of hemolysis. Another possible reason for this
finding is that the genes associated with bilirubin levels are all
involved in bilirubin catabolism and not production suggesting
that they are not reflective of the processes leading to bilirubin
formation.
In summary, SNPs in UGT1A1 are most tightly associated with
bilirubin levels in African Americans with sickle cell anemia. This
study in conjunction with those conducted in other populations at
risk for unconjugated hyperbilirubinemia and other cohorts of
sickle cell anemia patients support the concept that genetically
mediated differences in bilirubin conjugation play an important
role in the cholelithiasis risk. It is possible that targeting this
pathway pharmacologically may offer new therapeutic options for
these patients.
Supporting Information
Information S1 Description of the Bayesian hierarchical
model used to create the phenotype in the CSSCD
cohort. Supplementary Figure 1 contains information on the
LD structure of the UGT1A region in the CSCCD cohort.
Supplementary Table 1 contains information on the analysis of the
association between bilirubin and after adjusting for our most
significant SNP. Figure 1: LD Structure in CSSCD Cohort. LD
plots for regions in genes UGT1A1, UGT1A3, UGT1A4, UGT1A5,
UGT1A6, UGT1A7, UGT1A8, UGT1A9 and UGT1A10 on
chromosome 2 in the CSSCD subjects. The LD plot was
generated using Haploview 4.2. Each diamond represents the r2
value between two SNPs. The LD color scheme is: white r2 = 0,
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